Depomed Inc (NASDAQ:DEPO) has been given a consensus recommendation of “Hold” by the thirteen ratings firms that are currently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $10.72.
Several analysts recently weighed in on the company. Mizuho upgraded Depomed from a “neutral” rating to a “buy” rating and set a $9.00 price target on the stock in a research note on Tuesday, December 5th. BidaskClub upgraded Depomed from a “strong sell” rating to a “sell” rating in a research note on Thursday, February 15th. ValuEngine downgraded Depomed from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Royal Bank of Canada set a $9.00 price target on Depomed and gave the stock a “hold” rating in a research note on Thursday, December 7th. Finally, Roth Capital set a $10.00 price target on Depomed and gave the stock a “buy” rating in a research note on Friday, March 2nd.
In related news, SVP Matthew M. Gosling sold 45,519 shares of the firm’s stock in a transaction on Wednesday, March 7th. The stock was sold at an average price of $6.58, for a total value of $299,515.02. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Arthur J. Higgins bought 75,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 14th. The stock was bought at an average cost of $8.16 per share, for a total transaction of $612,000.00. The disclosure for this purchase can be found here. 2.59% of the stock is owned by corporate insiders.
Depomed (NASDAQ:DEPO) traded up $0.16 on Tuesday, reaching $7.17. The company’s stock had a trading volume of 2,153,606 shares, compared to its average volume of 1,380,000. The company has a market cap of $451.81, a price-to-earnings ratio of -5.83 and a beta of 1.10. The company has a debt-to-equity ratio of 3.21, a current ratio of 0.74 and a quick ratio of 0.70. Depomed has a fifty-two week low of $4.31 and a fifty-two week high of $16.29.
Depomed (NASDAQ:DEPO) last released its quarterly earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.10 by $0.05. The business had revenue of $94.41 million during the quarter, compared to analyst estimates of $88.75 million. Depomed had a negative return on equity of 45.19% and a negative net margin of 26.92%. analysts anticipate that Depomed will post -0.89 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece was first published by BBNS and is the sole property of of BBNS. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://baseballnewssource.com/2018/03/14/depomed-inc-depo-receives-consensus-rating-of-hold-from-brokerages/2026109.html.
Depomed, Inc is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl).
Receive News & Ratings for Depomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed and related companies with MarketBeat.com's FREE daily email newsletter.